Wonderfeel announces clinical study of its novel NMN supplement on human cells

Multipronged in vitro study focuses on the protection of human tissues from oxidant stress and inflammation and the optimal preservation of NMN for NAD production.

Wonderfeel, a company working towards accelerating wellness technologies through bioscience, has announced it has begun in vitro studies of its novel supplement, Youngr™ NMN. The study is intended to reveal the efficacy of Wonderfeel’s formula in providing cellular protection against tissue injury and dysfunction caused by oxidant stress and inflammation, which are among the leading causes of cellular decline and aging. The study’s parameters will also mimic physical exercise to gauge how efficiently Wonderfeel’s formula can help reduce the effects of exercise-induced stress and aid recovery.

Longevity.Technology: Wonderfeel is not a company that rests on its research laurels; having previously partnered with Abinopharm, to analyse, interpret and release the preliminary encouraging findings from a large double blind study on the effects of NMN, this new study is a critical step in validating some of Wonderfeel’s earlier work. The research will also set the stage for accelerating the company’s R&D with its NMN formulations on humans.

The company hopes that the information gleaned from this study will inform product development in both consumer and pharmaceutical applications, and we look forward to seeing the published results next year.

Each of the four components of Wonderfeel’s formula – NMN, ergothioneine, hydroxytyrosol and resveratrol at varying permutations – will be examined for their ability to preserve cellular levels of NAD and the health of the cells.

“Inflammation and oxidant stress are common causes of tissue injury and dysfunction,” Professor Andrew Salzman MD, Wonderfeel Chief Medical Officer, explains. “If left untreated over months and years, oxidant stress and inflammation can cause significant tissue damage.”

READ MORE: Youngr – on a mission to nurture and augment the effect of NMN

Baran Dilaver, CEO of Wonderfeel, adds: “Our study is expected to shed light on how the components act in synergy with NMN to enhance exercise performance and slow the progression of aging for healthy individuals. For those with medical conditions, Wonderfeel’s goal is to efficiently anticipate diseases and health challenges that are most likely to benefit from our NMN formulation.”

The in vitro study will be carried out at Salzman Group and led by Salzman, who already has more than 60 patents and 170 peer reviewed papers to his name.